What just happened? Aptose Biosciences Inc. (NASDAQ:APTO) stock value has plummeted by nearly -3.89% or (-0.11 points) to $2.72 from its previous close of $2.83. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 269129 contracts so far this session. APTO shares had a relatively better volume day versus average trading capacity of 394.49 thousand shares, but with a 50.2 million float and a -1.39% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for APTO stock indicates that the average analyst price target is $4.89 per share. This means the stock has a potential increase of 79.78% from where the APTO share price has been trading recently which is between $2.75 and $2.9906. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $7.93.
The shorts are running away from Aptose Biosciences Inc. (APTO) stock. The latest set of short interest data was released on 28 June 2019, and the numbers show a drop in short interest in APTO shares. While short interest still represents only 0.92% of APTO’s float, the number of shares shorted have fallen by -88757. The number of shares shorted fell to 462376 shares, down from 551133 shares during the preceding fortnight. With average daily trading volumes at 559609 shares, days to cover decreased to about 1.209166 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019” and dated July 23, 2019.
During the recent trading session for Aptose Biosciences Inc. (NASDAQ:APTO), the company witnessed their stock drop by $-0.14 over a week and surge $0.49 from the price 20 days ago. When compared to their established 52-week high of $3.2, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 09/10/18. The recent low of $1.57 stood for a -15% since 03/06/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.63 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Aptose Biosciences Inc., the two-week RSI stands at 54.06. This figure suggests that APTO stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current APTO readings is similarly very revealing as it has a stochastic reading of 52.84% at this stage. This figure means that APTO share price today is being neutral.
Technical chart claims that Aptose Biosciences Inc. (APTO) would settle between $2.96/share to $3.1/share level. However, if the stock price goes below the $2.72 mark, then the market for Aptose Biosciences Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $2.62 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.03. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
APTO equity has an average rating of 1.6, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 5 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 5 analysts rated Aptose Biosciences Inc. (NASDAQ:APTO) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.